NMPA Approves BioRay’s BR111, a Novel ROR1-Targeting ADC, for Clinical Trials “`

SHANGHAI, February 10, 2025 — BioRay Pharmaceutical Co., Ltd. announced on December 19, 2024, that the National Medical Products Administration (NMPA) has approved its clinical trial application for BR111, a novel, self-developed Class 1 therapeutic biologic. BR111, an antibody-drug conjugate (ADC), targets dual ROR1 epitopes to treat ROR1-positive hematologic malignancies…